Genenta Science S.p.A. (GNTA)
4.25
0.02 (0.47%)
At close: Jan 15, 2025, 2:13 PM
undefined% (undefined)
| Bid | 4.03 |
| Market Cap | 77.64M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.5 |
| PE Ratio (ttm) | -8.49 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 4.5 |
| Volume | 10,164 |
| Avg. Volume (20D) | 12,496 |
| Open | 4.30 |
| Previous Close | 4.23 |
| Day's Range | 4.04 - 4.30 |
| 52-Week Range | 2.20 - 7.28 |
| Beta | undefined |
About GNTA
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indic...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 15, 2021
Employees 14
Stock Exchange NASDAQ
Ticker Symbol GNTA
Website https://www.genenta.com
Analyst Forecast
According to 1 analyst ratings, the average rating for GNTA stock is "Buy." The 12-month stock price forecast is $25, which is an increase of 488.90% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
3 months ago ·
Source
+9.56%
Genenta Science shares are trading higher after th...
Unlock content with
Pro Subscription
